Skip to content

Early Diagnosis of Candidiasis in Premature Infants

Early Diagnosis of Nosocomial Candidiasis Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00109525
Acronym
Candida
Enrollment
1500
Registered
2005-04-29
Start date
2004-03-31
Completion date
2009-12-31
Last updated
2019-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candida, Candidiasis, Infant, Low Birth Weight, Infant, Newborn, Infant, Premature, Infant, Small for Gestational Age, Infection

Keywords

NICHD Neonatal Research Network, Fungal Infection, Mycosis, Extremely Low Birth Weight (ELBW), Prematurity, Clinical Judgement, Polymerase chain reaction (PCR) testing, Beta-glucan assay, Mass Spectrometry, Lumbar puncture

Brief summary

This observational study evaluated the performance of new lab tests in detecting candida species fungal infections in extremely low birth weight (ELBW) infants quickly and accurately. 19 NICHD Neonatal Research Network sites enrolled 1,500 infants with birth weights ≤1,000g; 100 of these infants later tested positive for candidiasis. Blood, urine, and lumbar puncture samples were collected whenever other specimens were obtained from participants for cultures. These samples are being tested using the new methods and compared with standard culture results. Surviving study subjects completed a neurodevelopmental evaluation at 18-22 months corrected age.

Detailed description

Candida species are a leading cause of infectious mortality in newborns with the incidence rates estimated at 4-18% in extremely low birth weight (ELBW) infants. 20-30% of these infants are likely to die. Because candida can invade virtually all body tissues (eyes, brain, heart, lung, liver, spleen, urinary tract, and joints), survivors of invasive Candida infections are at risk of blindness, developmental delays, and the need for surgical and other corrective procedures. Time is of the essence in detecting and treating these infections, with infant mortality from candidiasis largely attributed to duration of time for cultures to become positive for Candida. Diagnosis of candidiasis is challenging - blood and urine tests are slow (taking up to 72 hours to complete) and inaccurate in many cases, showing negative results despite overwhelming disease in adults as well as children. These problems are likely made worse in neonates, with smaller amounts of blood available for testing and infections that often spread to tissues inaccessible for testing. This observational study is evaluating the performance of new lab tests (beta-glucan assays, Gas Chromatography Mass Spectrometry for D-arabinitol, and polymerase chain reaction tests) compared to existing culture tests in detecting candida species fungal infections in extremely low birth weight (ELBW) infants quickly and accurately. In this study, 19 NICHD Neonatal Research Network sites enrolled 1,500 infants with birth weights ≤1,000g by 72 hours of life; more than 100 of these infants later tested positive for candidiasis. In the larger cohort, whenever cultures of blood or urine were obtained, or a lumbar puncture was done, additional samples and clinical data were collected. These additional samples are being tested using the new techniques under investigation. No additional blood specimens were taken once participants had a positive blood culture for candida. Note: Test procedure reagents are being provided the Duke University laboratory by Cape Cod Incorporated and Rockeby; the Thrasher Research Fund is also providing support to the Duke University laboratory. Surviving study subjects completed a neurodevelopmental evaluation at 18-22 months corrected age to evaluate potential early risk factors with long-term outcome.

Interventions

None listed

Sponsors

National Center for Research Resources (NCRR)
CollaboratorNIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
NICHD Neonatal Research Network
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Days to 120 Days
Healthy volunteers
Yes

Inclusion criteria

* Infants born ≤1,000g birth weight * Infants \>72 hours old and less than 120 days old

Exclusion criteria

* Prior positive blood culture for Candida * Evidence of congenital candidiasis * Parents/legal guardians refuse consent

Design outcomes

Primary

MeasureTime frame
Probability of invasive candidiasis based on new assay resultsUntil discharge
Determine test performance of clinical predictive modelUntil discharge

Secondary

MeasureTime frame
Determine test performance (sensitivity and specificity) of polymerase chain reaction (PCR) testingUntil discharge
Determine test performance of Beta-glucan assayUntil discharge
Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of blood samplesUntil discharge
Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of urine samplesUntil discharge
Determine test performance of the blood cultureUntil discharge
Determine test performance of the lumbar puncture (cell count, protein, glucose, and culture)Until discharge
Neurodevelopmental outcome18-22 months corrected age
Determine test performance of urine culturesUntil discharge
Compare clinical predictive model performance to neonatologist clinical judgmentUntil discharge
Determine incidence of end-organ damage in neonates with candidemiaUntil discharge
Determine resistance patterns of organisms isolatedUntil discharge
Determine molecular epidemiology of candidemiaUntil discharge
Determine test performance of tracheal aspiratesUntil discharge
Determine genetic expression of organism virulence factorsUntil discharge

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026